Healthcare & Health Industry Wire — Week of July 28, 2026
Candid Health's $120M Series D, the FDA's first TEMPO digital-health pilot participant, a proposed Medicaid provider-tax rule, an Idaho hospital ownership deal, and a practical glucose-data tip.
Candid Health raised $120 million in Series D funding for an artificial intelligence (AI)-first revenue cycle management (RCM) platform, while the U.S. Food and Drug Administration (FDA) selected Dexcom as the first participant in a digital-health pilot. The Centers for Medicare & Medicaid Services (CMS) proposed a major change to Medicaid provider-tax rules, and Intermountain Health agreed to buy Surgery Partners' stakes in two Idaho hospitals. For patients, the practical thread is how to use new glucose-data tools without mistaking an app's output for a personal treatment plan.
Loading stats card…
Health-tech funding and products
Candid Health raises $120M for autonomous medical billing
Candid Health raised $120 million in a Series D round led by Sixth Street Growth, with participation from Oak HC/FT, 8VC, and Y Combinator. The company sells an AI-first RCM platform for enterprise healthcare providers. Its system combines clinical, billing, and provider data, then uses a configurable rules engine and AI agents to handle manual billing work. 1
Sixth Street says Candid serves more than 200 healthcare organizations across dozens of specialties. The investor also reported 190% year-over-year growth in annual contracted run-rate revenue and 180% net dollar retention in 2025. The financing is earmarked for more automation, agentic RCM development, and hiring. 1
The operational question for provider groups is narrower than whether AI can write a claim. A billing platform still has to preserve the clinical and payer context behind that claim, expose errors for review, and make responsibility clear when an automated action is wrong. Candid's disclosed customer and revenue figures show commercial traction, but they do not by themselves establish lower denial rates or better patient bills.
Fierce Healthcare's detail page was not readable during this run, so this item uses the lead investor's announcement and a MedCity News report rather than attributing the figures to Fierce Healthcare. 2
Loading stats card…
Pharma and device FDA news
FDA names Dexcom as the first TEMPO digital-health pilot participant
The FDA announced on July 22 that Dexcom was the first manufacturer selected for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot. The selected program is Dexcom's Glucose Health Program, which is designed to give patients, caregivers, and healthcare professionals real-time data and artificial intelligence insights related to metabolic and nutritional status. 3
TEMPO is part of the FDA and CMS ACCESS model effort to collect, monitor, and report real-world data on how digital-health devices perform in intended use. The FDA says the Dexcom program is intended to support screening for prediabetes and type 2 diabetes and may help people with prediabetes improve glycemic control. The agency's selection process considers patient risk, expected benefit, and the manufacturer's plan for collecting and analyzing real-world data. 3
This is a pilot selection, not a new device clearance or an approval to treat diabetes. The near-term significance is evidence collection: manufacturers entering the program will need to report how a digital tool is used and what outcomes it produces in everyday care. That distinction matters for patients deciding how much weight to give a glucose app, a continuous glucose monitor (CGM), or an AI-generated suggestion.
Insurance and policy
CMS proposes a new Medicaid provider-tax framework
CMS published a proposed rule on July 21 to implement Section 71115 of Public Law 119-21 and revise the indirect "hold harmless" threshold for health care-related taxes, often called provider taxes. The proposal would add definitions and state reporting requirements, clarify how taxes are enacted and imposed, remove the second part of the existing 75/75 test, and recognize taxes on the services of health insurers as a permissible category under the proposed framework. 4
CMS says the historical mathematical test generally used a threshold of 6% of net patient revenue. The agency's actuary estimates that the proposed rule would reduce federal spending by $246 billion from 2026 through 2035. The new thresholds would generally begin October 1, 2026; for most permissible tax classes in states that expanded Medicaid to the adult group, implementation would begin October 1, 2027. Comments are due September 21, 2026. 4
The proposal is not a final payment cut or a final coverage rule. Its practical effect depends on how states and providers structure health care-related taxes, how the final rule defines permissible arrangements, and whether the implementation dates change after comments. Medicaid agencies, hospitals, and managed-care stakeholders have a specific September deadline for weighing in.
Loading stats card…
Hospital M&A
Intermountain to buy Surgery Partners' stakes in two Idaho hospitals
Surgery Partners entered an agreement to sell its ownership interests in Idaho Falls Community Hospital and Mountain View Hospital to Intermountain Health, an existing partner in both facilities. The deal values the hospitals at approximately $1.15 billion, with about $795 million in total consideration going to Surgery Partners. 5
Together, the Idaho Falls facilities have 126 beds and more than 150 physicians. They cover nine surgical specialties as well as oncology, an emergency department, an intensive care unit (ICU), and neonatology. The transaction is expected to close in the coming months, subject to customary conditions and approvals from Mountain View Hospital physician members and its physician governing board. 5
For the local market, this is an ownership-consolidation deal rather than a completed merger of two health systems. The items to watch are whether the closing changes physician governance, service availability, or referral patterns at the two hospitals. Those outcomes are not determined by the announced price alone.
Patient health tip
Use glucose data to prepare for a care conversation
The FDA's TEMPO announcement describes Dexcom's program as a way to provide real-time glucose data and AI insights. That can make a visit more concrete, but it does not set a personal target range or decide whether a medication should change. The Centers for Disease Control and Prevention (CDC) says blood-sugar targets vary with age, health, and the treatment plan, and that a clinician should determine when and how often a person checks. 3 6
Before your next appointment:
- Bring a recent glucose or CGM trend report, if you use one.
- Add brief notes about meals, activity, illness, and medication timing so a clinician can see the context around a pattern.
- Ask three direct questions: What is my personal target range? How often should I check? Which pattern should prompt a call or a change in the care plan?
The CDC notes that monitoring can reveal patterns and help a care team adjust a diabetes plan. Use an app or AI summary as supporting information, not as a reason to start, stop, or change treatment outside the plan you have made with your healthcare professional. 6
References
- 1Candid Health Raises $120M Led by Sixth Street Growth to Fuel Autonomous Revenue Cycle Management in Healthcare
- 2Candid Health Snags $120M for AI RCM Platform
- 3FDA Announces First Participant Selected for TEMPO for Digital Health Devices Pilot
- 4Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxes Proposed Rule (CMS-2452-P)
- 5Intermountain Health to acquire Surgery Partners' stake in 2 Idaho hospitals
- 6Monitoring Your Blood Sugar
Related content
- Sign in to comment.